Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552394 · ClinicalTrials.gov registry record · Phase 1
J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02552394 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 10 participants.
The verdict
NCT02552394, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This clinical trial is for men with advanced prostate cancer that may have spread to other parts of the body. Currently, once prostate cancer cells have spread from the prostate to other organs it is not treatable by surgery. The purpose of this study is to treat patients with an experimental antibody (i.e. that has not been FDA approved) called J591 that attaches itself to a special protein on cancer cells called PSMA to try to eliminate these cancer cells (called circulating tumor cells) from the circulation. In the initial phase of the study, 6 participants will receive the experimental J591 treatment. Routine blood tests, research blood tests, physical exam will be performed at each visit. Participants will also be asked to complete a questionnaire about how they are feeling. Participants will have a radiographic scan every 3 months to check the status of their disease. Participants who tolerate the treatment well may be re-treated at the same level every 3 months, and may continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.
Interventions
- DRUG huJ591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-07 |
| Est. Completion | 2021-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02552394
The ClinicalTrials.gov registry entry for NCT02552394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which huJ591 is the first listed.
NCT02552394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02552394 about?
NCT02552394 is a clinical study titled "J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts". This clinical trial is for men with advanced prostate cancer that may have spread to other parts of the body. Currently, once prostate cancer cells have spread from the prostate to other organs it is not treatable by surgery. The purpose of this study is to treat patients with an experimental antib...
What is the current status of trial NCT02552394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-07. Estimated completion is 2021-01-03.
What interventions are being tested in trial NCT02552394?
The interventions under investigation include: huJ591 (DRUG).
Who is sponsoring clinical trial NCT02552394?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.